Recurrent stroke and thrombo-occlusive events in the a

Annals of Neurology 38, 119-124 DOI: 10.1002/ana.410380119

Citation Report

#	Article	IF	CITATIONS
1	Antiphospholipid Antibody Syndrome. , 0, , 305-316.		0
3	1996 Diagnostic and Classification Criteria for the Antiphospholipid/Cofactors Syndrome: A â€~Mission Impossible'?. Lupus, 1996, 5, 354-363.	0.8	64
4	Treatment of Neurologic Complications of Antiphospholipid Antibody Syndrome. Lupus, 1996, 5, 473-476.	0.8	17
5	A diagnostic approach to ischemic stroke in young and middleâ€aged adults. European Journal of Neurology, 1996, 3, 324-330.	1.7	6
6	Neurological Aspects of Antiphospholipid Antibody Syndrome. Lupus, 1996, 5, 347-353.	0.8	71
7	Anticardiolipin Antibodies and the Risk of Recurrent Thrombo-occlusive Events and Death. Neurology, 1997, 48, 91-94.	1.5	92
8	Abnormal Cerebral Blood Flow Associated with Antiphospholipid Antibody Syndrome —Four Case Reports—. Neurologia Medico-Chirurgica, 1997, 37, 41-48.	1.0	1
9	Anticardiolipin antibodies in ischemic stroke in the young: Indian experience. Journal of the Neurological Sciences, 1997, 150, 137-142.	0.3	34
10	Manipulation of Coagulation Factors in Acute Stroke. Drugs, 1997, 54, 71-82.	4.9	5
11	Emerging risk factors for stroke: Patent foramen ovale, proximal aortic atherosclerosis, antiphospholipid antibodies, and activated protein C resistance. Journal of Stroke and Cerebrovascular Diseases, 1997, 6, 167-172.	0.7	11
12	Etiology of pediatric ischemic stroke. American Journal of Emergency Medicine, 1997, 15, 671-679.	0.7	17
13	The Feasibility of a Collaborative Double-Blind Study Using an Anticoagulant. Cerebrovascular Diseases, 1997, 7, 100-112.	0.8	66
14	Lupus anticoagulant and Sneddon's syndrome. European Journal of Neurology, 1997, 4, 408-412.	1.7	1
15	Coagulation disorders in young adults with acute cerebral ischaemia. Journal of Neurology, 1997, 245, 21-25.	1.8	61
16	A subgroup of multiple sclerosis patients with anticardiolipin antibodies and unusual clinical manifestations: Do they represent a new nosological entity?. Annals of Neurology, 1998, 44, 629-634.	2.8	132
18	LUPUS ANTICOAGULANTS AND ANTIPHOSPHOLIPID ANTIBODIES. Hematology/Oncology Clinics of North America, 1998, 12, 1167-1192.	0.9	30
19	Central nervous system vasculitis. Journal of the Neurological Sciences, 1998, 153, 159-171.	0.3	41
20	Multiple hemostatic abnormalities in young adults with activated protein C resistance and cerebral ischemia. Journal of the Neurological Sciences, 1998, 159, 209-212.	0.3	11

ATION RE

	CITATION I	LEPORT	
#	Article	IF	Citations
21	Neurological manifestations of antiphospholipid antibody syndrome. Lupus, 1998, 7, 67-74.	0.8	102
22	Towards improved criteria for the antiphospholipid syndrome. Lupus, 1998, 7, 149-157.	0.8	35
23	Anticoagulant and Defibrinogenating Agents in Acute Ischemic Stroke and Cerebral Venous Thrombosis. Seminars in Neurology, 1998, 18, 461-470.	0.5	6
24	Cerebrovascular Ischemic Events With High Positive Anticardiolipin Antibodies. Stroke, 1998, 29, 2245-2253.	1.0	102
25	Antiphospholipid-Protein Antibodies and Ischemic Stroke. Stroke, 1998, 29, 1755-1758.	1.0	56
26	Neurometabolite Markers of Cerebral Injury in the Antiphospholipid Antibody Syndrome of Systemic Lupus Erythematosus. Stroke, 1998, 29, 2254-2260.	1.0	85
27	Antiphospholipid Syndrome and Thrombosis. Seminars in Thrombosis and Hemostasis, 1999, 25, 333-350.	1.5	66
28	Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes. Lupus, 1999, 8, 127-133.	0.8	181
29	Anticardiolipin antibodies: a study in cerebral venous thrombosis. Acta Neurologica Scandinavica, 1999, 99, 121-124.	1.0	36
30	Study on relationship between anticardiolipin antibody and cerebrovascular diseases. Journal of Tongji Medical University, 1999, 19, 59-62.	0.1	0
31	Thrombosis in sickle cell disease. Translational Research, 1999, 134, 329-330.	2.4	7
32	White Thread-Like Retinal Arterioles Associated With Antiphospholipid Antibody Syndrome. Japanese Journal of Ophthalmology, 1999, 43, 553-558.	0.9	3
33	Gradually Progressive Dementia Without Discrete Cerebrovascular Events in a Patient With Sneddon's Syndrome. Mayo Clinic Proceedings, 1999, 74, 57-61.	1.4	30
34	Serum anti-β2-glycoprotein-I and anticardiolipin antibodies during thrombosis in systemic lupus erythematosus patients. American Journal of Medicine, 1999, 106, 417-423.	0.6	69
35	Anticardiolipin antibodies are an independent risk factor for ischemic stroke. Neurological Research, 1999, 21, 653-657.	0.6	40
37	Antiphospholipid Syndrome with Cortical Blindness Resulting from Infarction Around the Posterior Cerebral Artery in an Elderly Woman Internal Medicine, 2000, 39, 587-591.	0.3	3
38	Diagnostic Testing for Coagulopathies in Patients With Ischemic Stroke. Stroke, 2000, 31, 3067-3078.	1.0	153
39	The clinical significance of antiphospholipid antibodies in patients without autoimmune disease. Australian and New Zealand Journal of Medicine, 2000, 30, 693-703.	0.5	2

	CITATION R	CITATION REPORT	
#	Article	IF	CITATIONS
40	Transcranial Doppler patterns in patients with anticardiolipin antibodies. Radiography, 2000, 6, 83-87.	1.1	1
41	Antiphospholipid antibody syndrome. Current Treatment Options in Neurology, 2000, 2, 449-457.	0.7	13
42	Which Antiphospholipid Antibodies Should Be Measured in the Antiphospholipid Syndrome?. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2000, 30, 57-62.	0.5	9
43	Differential Diagnosis of Central Nervous System Manifestations of the Antiphospholipid Antibody Syndrome. Journal of Autoimmunity, 2000, 15, 133-138.	3.0	33
45	State-of-the-Art Review: Antiphospholipid Thrombosis Syndromes. Clinical and Applied Thrombosis/Hemostasis, 2001, 7, 241-258.	0.7	34
46	WHICH ANTIPHOSPHOLIPID ANTIBODY TESTS ARE MOST USEFUL?. Rheumatic Disease Clinics of North America, 2001, 27, 525-549.	0.8	14
47	Spectrum of antiphospholipid antibodies (aPL) in patients with cerebrovascular disease. Journal of Stroke and Cerebrovascular Diseases, 2001, 10, 222-226.	0.7	24
48	Importance des anticorps antiphospholipides en clinique. Immuno-Analyse Et Biologie Specialisee, 2001, 16, 103-109.	0.0	Ο
49	HUGHES (ANTIPHOSPHOLIPID) SYNDROME. Rheumatic Disease Clinics of North America, 2001, 27, 507-524.	0.8	34
50	Use of specialized coagulation testing in the evaluation of patients with acute ischemic stroke. Neurology, 2001, 56, 624-627.	1.5	36
51	Neurologic manifestations of the antiphospholipid syndrome. Current Rheumatology Reports, 2001, 3, 286-292.	2.1	28
52	Recurrent stroke and vascular events in elderly patients with anticardiolipin antibodies: a prospective study. Journal of Neurology, 2001, 248, 373-379.	1.8	31
53	Acquired thrombophilic syndromes. Blood Reviews, 2001, 15, 31-48.	2.8	13
54	Antiphospholipid Antibodies and Stroke in Young Women. Stroke, 2002, 33, 2396-2401.	1.0	125
55	Antiphospholipid Antibodies in the Acute Phase of Cerebral Ischaemia in Young Adults: A Descriptive Study of 139 Patients. Cerebrovascular Diseases, 2002, 13, 156-162.	0.8	37
56	Prevalence and clinical features of dementia associated with the antiphospholipid syndrome and circulating anticoagulants. Journal of the Neurological Sciences, 2002, 203-204, 81-84.	0.3	50
57	Therapy of Sneddon Syndrome. European Neurology, 2002, 48, 126-132.	0.6	39
58	Primary Anti-Phospholipid Antibody Syndrome (APS). Survey of Ophthalmology, 2002, 47, 215-238.	1.7	78

#	ARTICLE	IF	CITATIONS
59 60	Antiphospholipid Syndrome and Multiple Ischemic Strokes in a Patient with Myasthenia Gravis Kurume Medical Journal, 2002, 49, 211-216.	0.0	4
61	Anticardiolipin antibody in vascular parkinsonism. Movement Disorders, 2002, 17, 992-997.	2.2	22
62	Lupus vasculitis: Differential diagnosis with antiphospholipid syndrome. Current Rheumatology Reports, 2002, 4, 18-24.	2.1	26
64	Neurological and Neuroendocrineâ€Cytokine Interâ€relationship in the Antiphospholipid Syndrome. Annals of the New York Academy of Sciences, 2002, 966, 415-424.	1.8	21
65	Screening for hypercoagulable syndromes following stroke. Current Atherosclerosis Reports, 2003, 5, 291-298.	2.0	12
66	Antiphospholipid thrombosis syndromes. Hematology/Oncology Clinics of North America, 2003, 17, 115-147.	0.9	39
67	Accidente cerebrovascular isquémico en la fase establecida. Medicine, 2003, 8, 4925-4932.	0.0	0
68	Central nervous system lupus: a clinical approach to therapy. Lupus, 2003, 12, 935-942.	0.8	74
69	Autoimmune optic neuropathy with anticardiolipin antibody mimicking multiple sclerosis in a child. American Journal of Ophthalmology, 2003, 136, 358-360.	1.7	22
70	Intraocular pressure in patients with human immunodeficiency virus and treated with highly active antiretroviral therapy. American Journal of Ophthalmology, 2003, 136, 360-361.	1.7	3
71	Clinical and epidemiological aspects in the antiphospholipid syndrome. Immunobiology, 2003, 207, 5-11.	0.8	50
72	In vivo characterization of bioconjugate B cell toleragens with specificity for autoantibodies in antiphospholipid syndrome. International Immunopharmacology, 2003, 3, 1667-1675.	1.7	7
73	Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer. Lupus, 2003, 12, 436-442.	0.8	119
74	Left-sided heart valve abnormalities and risk of ischemic cerebrovascular accidents in patients with systemic lupus erythematosus. Lupus, 2003, 12, 805-812.	0.8	35
75	CNS dysfunction in the antiphospholipid syndrome. Lupus, 2003, 12, 903-907.	0.8	78
76	Stroke and the antiphospholipid syndrome: consensus meeting Taormina 2002. Lupus, 2003, 12, 508-513.	0.8	71
77	Central nervous system involvement in the antiphospholipid (Hughes) syndrome. British Journal of Rheumatology, 2003, 42, 200-213.	2.5	133

CITATION REPORT

	CITATION R	EPORT	
#	Article	IF	CITATIONS
78	Coagulopathies and Arterial Stroke. Journal of Neuro-Ophthalmology, 2003, 23, 63-71.	0.4	41
79	Case 21-2003. New England Journal of Medicine, 2003, 349, 170-180.	13.9	35
80	Cerebrovascular Disease in Italy and Europe: It Is Necessary to Prevent a â€~Pandemia'. Gerontology, 2003, 49, 69-79.	1.4	8
81	Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood, 2003, 101, 1827-1832.	0.6	892
82	The clinical aspects of the antiphospholipid syndrome. , 2004, , 1107-1123.		2
83	THE ANTIPHOSPHOLIPID SYNDROME: PATHOGENESIS AND IMPLICATIONS FOR SYSTEMIC LUPUS ERYTHEMATOSUS. , 2004, , 1161-1184.		0
84	Coagulation Abnormalities in Stroke. , 2004, , 707-724.		0
86	Current Debates in Antiphospholipid Syndrome: The Acquired Antibody-Mediated Thrombophilia. Clinical and Applied Thrombosis/Hemostasis, 2004, 10, 89-126.	0.7	17
87	Thrombophilic risk factors and unusual clinical features in three Italian CADASIL patients. European Journal of Neurology, 2004, 11, 782-787.	1.7	23
88	Do antiphospholipid antibodies increase the long-term risk of thrombotic complications in young patients with a recent TIA or ischemic stroke?. Acta Neurologica Scandinavica, 2004, 109, 410-415.	1.0	34
89	Prevalence and isotype distribution of antiphospholipid antibodies in unselected Chilean patients with venous and arterial thrombosis. Clinical Rheumatology, 2004, 23, 129-133.	1.0	17
90	Management of the neurological manifestations of APS—what do the trials tell us?. Thrombosis Research, 2004, 114, 489-499.	0.8	42
91	Controversies in the antiphospholipid syndrome and stroke. Thrombosis Research, 2004, 114, 483-488.	0.8	8
95	Hughes Syndrome, the Antiphospholipid Syndrome: A New Chapter in Neurology. Annals of the New York Academy of Sciences, 2005, 1051, 465-486.	1.8	45
96	The Immunologic Basis, Neurological Manifestations and Management of The Anti Phospholipid Antibody Syndrome. Apollo Medicine, 2005, 2, 4-9.	0.0	0
97	Antiphospholipid Antibodies in Young Adults with Stroke. Journal of Thrombosis and Thrombolysis, 2005, 20, 105-112.	1.0	56
98	Antiphospholipid Antibodies Bind ATP: A putative Mechanism for the Pathogenesis of Neuronal Dysfunction. Clinical and Developmental Immunology, 2005, 12, 175-180.	3.3	14
99	Diagnosis of antiphospholipid syndrome. Nature Clinical Practice Rheumatology, 2005, 1, 40-46.	3.2	29

CITATION REPORT

#	Article	IF	CITATIONS
100	Mitral Valve Replacement in a Patient With Sneddon Syndrome. Journal of Cardiothoracic and Vascular Anesthesia, 2005, 19, 661-664.	0.6	8
101	Predictive role of hs-C-reactive protein in patients with antiphospholipid syndrome. Immunobiology, 2005, 210, 755-760.	0.8	12
103	Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack. Stroke, 2006, 37, 577-617.	1.0	1,510
104	Cerebral Manifestations in the Antiphospholipid (Hughes) Syndrome. Rheumatic Disease Clinics of North America, 2006, 32, 465-490.	0.8	77
105	Prevalence of antiphospholipid antibodies in patients with neurological symptoms. Clinical Neurology and Neurosurgery, 2006, 108, 135-142.	0.6	30
106	Cerebral Ischemia in Antiphospholipid Syndrome. , 2006, , 53-67.		0
107	Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack. Circulation, 2006, 113, .	1.6	416
108	Hereditary and acquired thrombophilia in pregnancy. , 2006, , 122-199.		0
109	Primary antiphospholipid syndrome: A distinct entity?. Autoimmunity Reviews, 2006, 5, 70-75.	2.5	22
110	Relationship between serum NR2a antibodies and cognitive dysfunction in systemic lupus erythematosus. Arthritis and Rheumatism, 2006, 54, 2515-2522.	6.7	117
112	Evoked potential studies in the antiphospholipid syndrome: differential diagnosis from multiple sclerosis. Annals of the Rheumatic Diseases, 2006, 65, 525-528.	0.5	10
113	Unusual Clinical Manifestations of the Antiphospholipid Syndrome. Current Rheumatology Reviews, 2006, 2, 387-394.	0.4	3
114	Stroke and Other Neurovascular Disorders. , 2007, , 1019-1051.		4
115	Antiphospholipid Syndrome and Vascular Ischemic (Occlusive) Diseases: An Overview. Yonsei Medical Journal, 2007, 48, 901.	0.9	23
116	Neonatal cerebral ischaemia with elevated maternal and infant anticardiolipin antibodies. Developmental Medicine and Child Neurology, 2007, 42, 412-413.	1.1	1
118	Neurologic Symptoms as a Feature of the Antiphospholipid Syndrome. Seminars in Thrombosis and Hemostasis, 2008, 34, 286-289.	1.5	25
119	Neuropsychiatric Involvement in Systemic Lupus Erythematosus:Current Therapeutic Approach. Current Pharmaceutical Design, 2008, 14, 1261-1269.	0.9	74
120	Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack. Stroke, 2011, 42, 227-276.	1.0	1,433

#	Article	IF	CITATIONS
121	Clinical Presentation of Antiphospholipid Syndrome. , 2011, , 1001-1014.		0
123	Antiphospholipid antibodies and the brain: A consensus report. Lupus, 2011, 20, 153-157.	0.8	39
125	Transient ischemic attack and stroke in systemic lupus erythematosus. Lupus, 2013, 22, 1251-1258.	0.8	30
126	Revisiting the Molecular Mechanism of Neurological Manifestations in Antiphospholipid Syndrome: Beyond Vascular Damage. Journal of Immunology Research, 2014, 2014, 1-9.	0.9	35
127	Antiphospholipid antibody syndrome. Clinical Queries Nephrology, 2014, 3, 9-14.	0.2	0
128	Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack. Stroke, 2014, 45, 2160-2236.	1.0	3,891
129	Antiphospholipid antibodies as biomarkers in psychiatry: review of psychiatric manifestations in antiphospholipid syndrome. Translational Developmental Psychiatry, 2015, 3, 25452.	0.3	11
130	Antiphosphatidylserine Antibodies and Clinical Outcomes in Patients With Acute Ischemic Stroke. Stroke, 2016, 47, 2742-2748.	1.0	13
131	Clinical presentation of antiphospholipid syndrome. , 2021, , 561-574.		0
132	CLINICAL SIGNIFICANCE OF APTT - ANTIPHOSPHOLIPID ANTIBODY SYNDROME PRESENTING AS STROKE , 2021, , 1-2.		0
133	The Primary Antiphospholipid Syndrome. , 2000, , 111-126.		7
134	Cerebral Disease in the Antiphospholipid Syndrome. , 2000, , 43-58.		8
136	Neonatal cerebral ischaemia with elevated maternal and infant anticardiolipin antibodies. Developmental Medicine and Child Neurology, 2000, 42, 412-413.	1.1	36
137	Branch Retinal Artery Occlusion Secondary to Antiphospholipid Syndrome. Optometry and Vision Science, 2012, 89, e78-e84.	0.6	5
138	Thrombogenic Properties of Murine Anti-Cardiolipin Antibodies Induced by β ₂ Glycoprotein 1 and Human Immunoglobulin G Antiphospholipid Antibodies. Circulation, 1996, 94, 1746-1751.	1.6	106
139	lgG Anticardiolipin Antibody Titer >40 GPL and the Risk of Subsequent Thrombo-occlusive Events and Death. Stroke, 1997, 28, 1660-1665.	1.0	185
140	Antiphospholipid Antibody and Recurrent Ischemic Stroke. Stroke, 2020, 51, 3728-3732.	1.0	9
141	Anticardiolipin Antibodies in Young Saudis with Ischemic Stroke. Annals of Saudi Medicine, 1998, 18, 73-74.	0.5	1

CITATION REPORT

8

		CITATION REPORT	
# 142	ARTICLE Laboratory Evaluation of Hypercoagulability With Venous or Arterial Thrombosis. Archives of Pathology and Laboratory Medicine, 2002, 126, 1281-1295.	IF 1.2	Citations 66
143	Hypercoagulation Testing in Ischemic Stroke. Archives of Pathology and Laboratory Medicine, 131, 890-901.	2007, 1.2	43
144	Cerebrovascular Disease in Women. , 2000, , 797-810.		1
145	Pathogenesis of Stroke in Young Adults. , 2000, , 401-407.		0
146	Anticoagulation Therapy for the Antiphospholipid Syndrome. , 2001, , .		0
147	Vascular Manifestations in the Antiphospholipid Syndrome. , 2001, , .		Ο
148	Anticoagulation Therapy for the Antiphospholipid Syndrome. , 2001, , 583-590.		0
149	Course and Prognosis of the Antiphospholipid Syndrome. , 2002, , 409-419.		1
150	Cardiac and cerebral Manifestations of the Antiphospholipid Syndrome. , 2003, , 260-265.		0
151	Cryptogenic Emboli and Other Elusive Causes of Stroke. , 2004, , 199-225.		0
152	引皮症ã«å•̂ä½µã⊷ã¥æŠ—ãƒªãƒ³è,,,質抗体症候ç¾₿«ä¼′ã†å†…é,å‹•è,,^ã®oscill	ating thrombusã,'èªã, ãẍè ,	,³å¡žæðã®ä,€ä¾∢
153	THE CLINICAL ASPECTS OF THE ANTIPHOSPHOLIPID SYNDROME. , 2004, , 1107-1123.		1
154	Neurological Manifestations of Vasculitis. , 2007, , 901-911.		0
158	Neurologic Complications. , 2011, , 861-891.e5.		0
159	Task Force Report on Brain Involvement in Antiphospholipid Syndrome. , 2012, , 159-166.		0
162	Acute longitudinal myelitis as the first presentation in child with systemic lupus erythematosu concurrent with positive antiphospholipid antibody. Acta Medica International, 2015, 2, 168.	s	О
163	Recommended Therapeutic INR Range for Patients with Antiphospholipid Syndrome on Warfa Anticoagulation: Is Moderate-Intensity (INR 2.0 - 3.0) or High-Intensity (INR 3.1 - 4.0) Better for Risk of Recurrent Thromboembolic Events?. Cureus, 2016, 8, e765.	rin vr Reducing 0.2	7

Anti-phospholipid antibody syndrome. , 0, , 263-274.

9

#	Article	IF	CITATIONS
167	Rare stroke mechanisms in 4154 consecutive patients: causes, predictors, treatment, and outcomes. Neurological Sciences, 2022, 43, 6359-6369.	0.9	2